NCT04920682View on ClinicalTrials.gov

Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 21, 2021

Conditions
NeostigmineNeuromuscular Blocking AgentsMuscle Weakness
Interventions
DRUG

Reversal of moderate neuromuscular blockade

Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4

DRUG

Reversal of superficial neuromuscular blockade

Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4

DRUG

Two-step reversal

Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4

DRUG

Placebo

0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4

Trial Locations (1)

18030-230

Santa Lucina Hospital, Sorocaba

All Listed Sponsors
lead

Pontificia Universidade Catolica de Sao Paulo

OTHER